Investigating the occurrence of everolimus long-term side effects by follow up of everolimus trough blood concentrations. - Everolimus TDM to predict long-term toxicity

Medisch Universitair Ziekenhuis Maastricht0 个研究点目标入组 40 人待定

概览

阶段: 4 期
干预措施: 未指定
疾病 / 适应症: 未指定
发起方: Medisch Universitair Ziekenhuis Maastricht
入组人数: 40
状态: 招募中
最后更新: 2年前

概览研究者入排标准结局指标相似试验

概览

简要总结

暂无简介。

注册库

who.int

开始日期

待定

结束日期

待定

最后更新

2年前

研究类型

Observational invasive

研究者

发起方

Medisch Universitair Ziekenhuis Maastricht

入排标准

入选标准

•\-Patients currently treated with everolimus for any type of cancer, such as the
•EMA registered indications i.e. advanced (Hormone\-Receptor \[HR]\-positive,
•HER2\-negative) breast cancer, metastatic renal cell carcinoma (mRCC) or
•neuroendocrine tumour (NET) of pancreatic, gastrointestinal or lung origin.
•\-Aged 18 or above
•\-Able and willing to sign the informed consent

排除标准

•\-No informed consent
•\-Alactasia
•\-Lenvatinib combination therapy with everolimus (mRCC)

结局指标

主要结局

未指定

相似试验

进行中（未招募）

1 期

Introduction of everolimus is associated with a reduction in the dosage of calcineurine-inhibitors in patients with a pulmonary graft who suffer from a notable chronic renal insuffisance.Patient who received a pulmonary transplant and who show notable renale insuffisance (DFG < 50ml/min/1.73m²) which has been progressive over the last two years or chronical renal insuffisance which progresses fast (a los of >50% DGF in 3 months) and isotopical glomerural filtration < 45 ml/min.

EUCTR2006-001945-32-BEB Erasme15

已完成

2 期

Everolimus added to long acting octreotide as a volume reducing treatment of polycystic livers.polycystic liver disease10019654

NL-OMON32654niversitair Medisch Centrum Sint Radboud44

进行中（未招募）

1 期

Everolimus added to long acting octreotide as a volume reducing treatment of polycystic livers. - ELATEIsolated polycystic liver diseaseMedDRA version: 12.1Level: LLTClassification code 10048834Term: Polycystic liver diseaseMedDRA version: 12.1Level: PTClassification code 10048834Term: Polycystic liver disease

EUCTR2009-016640-39-NLRadboud University Nijmegen Medical Centre44

招募中

不适用

Study examining the PROMUS Element everolimus-eluting stent in multi-center Coronary Intervention of complex Arterial Lesion Subsets (OCT and IVUS sub analysis)Complex coronary artery disease

JPRN-UMIN000021122The PCI Guideline Research Society50

尚未招募

不适用

Study examining the PROMUS Element everolimus-eluting stent in multi-center Coronary Intervention of complex Arterial Lesion Subsets

JPRN-UMIN000008651The PCI Guideline Research Society800